Clinical trials: Multiple Dose
Psoriasis
Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject
To evaluate the safety and tolerability of UCB5857. Part 1 of the study explores single doses of the drug. Part 2 of the study explores giving the drug every day for 14 days. The study uses healthy and psoriasis subjects.
- Trial name
- NCT02303509
- Testing
- UCB5857 Part 1, UCB5857 Part 2
- Where
- United Kingdom
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Healthy
A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study).
- Trial name
- NCT07548606
- Testing
- Opevesostat, Prednisone, Fludrocortisone acetate
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Participants
A Single- and Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2059 Powder for Inhalation
Randomized, double-blind and placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic characteristics of SYH2059 powder for inhalation after single and multiple doses in healthy subjects.
- Trial name
- NCT07510958
- Testing
- SYH2059
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- InnovStone Therapeutics Limited
Cardiovascular Diseases
A First-in-human Study of YN001 in Healthy Volunteers
This will be a single center, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study in healthy adult subjects.
- Trial name
- NCT05635084
- Testing
- YN001
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Beijing Inno Medicine Co., Ltd.
Healthy Volunteers
A Study of RO7890597 in Healthy Adult Volunteers
This study will evaluate the safety, pharmacokinetics (PK), and activity of single and multiple doses of RO7890597 compared with placebo in healthy volunteers.
- Trial name
- NCT07797478
- Testing
- RO7890597, Rabeprazole, Itraconazole
- Where
- United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Parkinson's Disease
A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects
The principal aim of this study is to obtain safety and tolerability data when PXT002331 is administered orally as single and multiple doses to healthy subjects.
- Trial name
- NCT02639221
- Testing
- PXT002331
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Prexton Therapeutics
Moderate-to-severe Atopic Dermatitis
Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis
This Phase 1a/1b randomized, double-blind, placebo-controlled study evaluates the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously (SC) administered TRB-061 in healthy adults and patients with…
- Trial name
- NCT06934252
- Testing
- TRB-061
- Where
- 19 sites in Australia, New Zealand
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- TRex Bio, Inc.
Bacterial Infections
Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single rising and multiple rising IV doses of TR-701 FA and to determine the absolute bioavailability of oral TR-701 FA following single…
- Trial name
- IV/SAD/MAD (NCT00983255)
- Testing
- TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Obstructive Sleep Apnea
A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose
BAY2586116 is a new drug in development for the treatment of obstructive sleep apnea. This is a condition that causes breathing to repeatedly stop and start during sleep due to blocked upper airways.
- Trial name
- NCT04872387
- Testing
- BAY2586116
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Subjects, Pharmacokinetics of ASP2205
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205
The purpose of this study is to evaluate the safety and tolerability of single ascending oral doses of ASP2205 in healthy young male and female subjects.
- Trial name
- NCT02314793
- Testing
- ASP2205
- Where
- United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
HIV
A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1
This study is testing a lab-made antibody called ePGT121v1-LS that targets a specific part of HIV. Researchers will give it by vein (IV) and under the skin (SC), both on its own and together with two other antibodies, VRC07-523LS…
- Trial name
- NCT07390955
- Testing
- ePGT121v1-LS (IV), PGDM1400LS (IV), VRC07-523LS (IV)
- Where
- 11 sites in United States, Peru and 1 more
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Moderate to Severe Asthma
Study of Multiple Ascending Dose of KBL693 in Healthy Participants
The study is designed to investigate the safety and tolerability of KBL693 in healthy volunteers. KBL693 has been developed as a potential new treatment for moderate to severe asthma..
- Trial name
- NCT04307173
- Testing
- KBL693
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- KoBioLabs
Healthy Volunteer
A Study of RO5267683 in Healthy Subjects
This investigator-blind, subject-blind, randomized, placebo-controlled study will evaluate the safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of RO5267683 in healthy volunteers.
- Trial name
- NCT01398241
- Testing
- RO5267683
- Where
- France
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Overweight, Obesity
A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants
This is a randomized, investigator-and-participant-blind, placebo-controlled, fixed sequence, cross-over, Phase 1 study to investigate the safety, tolerability, and pharmacokinetics of multiple doses of orally administered…
- Trial name
- NCT06982131
- Testing
- RO7795081, Rosuvastatin, Pitavastatin
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Overweight and Obesity
A Phase 1, Double-blind, Randomized Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Dose and Multiple Doses of CG-0416 in Healthy Participants.
A Phase 1, double-blind, randomized study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of single dose and multiple doses of CG-0416 in healthy participants. HongKong Curegene Innovation Co.
- Trial name
- NCT07724431
- Testing
- CG-0416
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- HongKong Curegene Innovation Co., Limited
Helicobacter Pylori Associated Gastrointestinal Disease
Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers
To evaluate the effect of coadministration of amoxicillin and clarithromycin on safety, tolerability and pharmacokinetics of JP-1366 in healthy subjects and the effect of JP-1366 on safety, tolerability and pharmacokinetics of…
- Trial name
- NCT05194046
- Testing
- JP-1366 20mg 1capsule, Amoxicillin 500Mg Cap, Clarithromycin 500Mg Tab
- Where
- South Korea
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Onconic Therapeutics Inc.
Healthy Participants
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants
The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and…
- Trial name
- NCT07290283
- Testing
- AZD3974
- Where
- 2 sites in United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers
A study to assess multiple ascending doses of AR882 in healthy adult males.
- Trial name
- NCT04314986
- Where
- Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Arthrosi Therapeutics
Healthy Volunteer, Type 2 Diabetes
A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477
This study is designed to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO6799477 following once daily oral administration for 2 weeks in healthy volunteers (Part 1) and in Type 2 diabetes…
- Trial name
- NCT02164266
- Testing
- RO6799477
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects
This is a first in human study of ETD002 a new drug being developed for the treatment of cystic fibrosis.The study is a randomised, double-blind, placebo-controlled, interventional study to assess the safety and tolerability of…
- Trial name
- NCT04488705
- Testing
- ETD002 - single dose, ETD002 - 7 day repeat dose, ETD002 - 14 day repeat dose
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Enterprise Therapeutics Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.